These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15930888)

  • 1. Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience.
    Bartsch R; Wenzel C; Sevelda U; Hussian D; Pluschnig U; Locker GJ; Mader R; Zielinski CC; Steger GG
    Anticancer Drugs; 2005 Jul; 16(6):617-20. PubMed ID: 15930888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
    Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G; Llorca C; Cervera JM; Orts D; Juárez A; Carrato A
    Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
    J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
    Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
    Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH
    Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
    Boccia RV; Henry DH; Belton L; Bohac C; Ghazal HH
    Cancer Med; 2016 Dec; 5(12):3445-3453. PubMed ID: 27882724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
    Esquerdo G; Doménech M; López P; Pedro C; Villadiego K; Constenla M; Sánchez-Rovira P; Gasquet JA; Rodríguez CA;
    Tumori; 2014; 100(2):225-31. PubMed ID: 24852870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia.
    Bloomfield M; Jaresko G; Zarek J; Dozier N
    Pharmacotherapy; 2003 Dec; 23(12 Pt 2):110S-118S. PubMed ID: 14695000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.